New Test Launched

The MammaPrint is a genomic test that analyzes the activity of certain genes in early-stage breast cancer. The MammaPrint Test is used in two ways:

• Research suggests the MammaPrint test eventually may be used to estimate a woman’s recurrence risk for early-stage breast cancer that is hormone-receptor-positive or hormone-receptor-negative.
• The MammaPrint test analyzes 70 genes using a microarray-based gene expression profile to see how active they are and then calculates either a high-risk or a low-risk recurrence score

Who’s eligible for the MammaPrint test?

MammaPrint can only be used to analyze early-stage breast cancers that are:

• Stage I or stage II
• Invasive
• Smaller than 5 centimeters
• Estrogen-receptor-positive or -negative

In both the United States and internationally, MammaPrint can be used to analyze cancers that are hormone-receptor-positive and hormone-receptor-negative.

How does the MammaPrint test work?

The MammaPrint test looks at the activity of 70 genes and then calculates a recurrence score that is either low risk or high risk.

If a patient decide to have the MammaPrint test, a patient and a patient’s doctor will consider a number of factors when deciding on whether to add chemotherapy to a patient treatment plan, including:

• A patient age
• The size of the cancer
• Cancer grade
• Whether cancer cells were found in nearby lymph nodes
• A patient general health